<DOC>
	<DOCNO>NCT02909036</DOCNO>
	<brief_summary>Captisol Enabled Melphalan , new formulation standard care melphalan chemotherapy package inactive substance believe help chemotherapy stable ( mean n't lose effect need administer quickly mixed ) . It may also fewer side effect problem important level body electrolytes potassium , phosphorous magnesium ; cause less kidney heart damage ] standard formulation melphalan . The purpose study determine investigator achieve certain level Captisol Enabled Melphalan would best use treat Multiple Myeloma AL Amyloidosis .</brief_summary>
	<brief_title>Study Captisol Enabled Melphalan Pharmacokinetics Patients With Multiple Myeloma Light Chain Amyloidosis That Are Receiving Autologous Transplant .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Age ≥18 ≤ 75 Patients must either : Symptomatic multiple myeloma respond prior induction salvage chemotherapy ( i.e . chemosensitive disease ) : Patients receive highdose melphalan AHCT part initial therapy require least partial response ( PR ) define International Myeloma Working Group uniform response criterion MM . Patients receive highdose melphalan AHCT part salvage therapy require least minor response last line therapy document chemosensitive disease . There limit number prior regimen receive patient . OR Light chain ( AL ) amyloidosis may newly diagnose previously treat Histologic serologic finding , review MSKCC , confirm diagnosis multiple myeloma AL amyloidosis . Standard diagnostic criterion multiple myeloma use , per International Myeloma Foundation consensus guideline Patients must least 3 x 10^6 CD34+ cells/kg frozen . Adequate organ function require , defined follow : Serum bilirubin ≤ 2.0 mg/dl AST , ALT alkaline phosphatase &lt; 3 time upper limit laboratory normal Creatinine clearance ≥ 40 ml/min ( 24 hour urine collection ) LVEF ≥ 45 % MUGA rest ECHO Diffusing capacity ≥ 45 % ( adjust hemoglobin ) predict pulmonary function test Performance status ( ECOG ) ≤ 2 A willingness avoid pregnancy father child male female subject respectively A woman childbearing potential must negative serum pregnancy test ( βhuman chorionic gonadotropin [ βhCG ] ) screen must willing avoid pregnancy study treatment period specify duration ( 1 year post HCT ) end treatment . Women childbearing potential negative serum pregnancy test screening must practice highly effective method birth control ( least 99 % certainty ) screen safety followup . Permitted method least 99 % effective preventing pregnancy communicate subject understanding confirm . Men enrol must agree take appropriate precaution avoid father child ( least 99 % certainty ) screen safety followup . Permitted method least 99 % effective preventing pregnancy communicate subject understanding confirm Unstable angina myocardial infarction within 4 month initiate therapy trial , NYHA Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , sick sinus syndrome , electrocardiographic evidence acute ischemia Grade 3 conduction system abnormalities unless subject pacemaker Light chain ( AL ) amyloidosis patient Mayo Cardiac Stage III ( define NTproBNP &gt; 332 ng/L Cardiac troponin ( cTnT ) &gt; 0.035 μg/L ) Pregnant lactate female Nonhematologic malignancy within past 3 year exception ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; b ) carcinoma situ cervix breast ; c ) prostate cancer Gleason Grade 6 less stable prostatespecific antigen level ; ) cancer consider cure surgical resection unlikely impact survival duration study , localize transitional cell carcinoma bladder benign tumor adrenal pancreas Contraindication CE melphalan require supportive treatment , include hypersensitivity GCSF pegfilgrastim Any medical condition laboratory evaluation , treat physician 's principal investigator 's opinion , make patient unsuitable participate clinical trial Any known allergy allergic reaction Captisol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Melphalan</keyword>
	<keyword>Autologous Hematopoietic Progenitor Cell Transplant</keyword>
	<keyword>High Dose Therapy</keyword>
	<keyword>16-875</keyword>
</DOC>